| Pharmaceutical industry–sponsored meals and physician prescribing patterns for Medicare beneficiaries C DeJong, T Aguilar, CW Tseng, GA Lin, WJ Boscardin, RA Dudley JAMA internal medicine 176 (8), 1114-1122, 2016 | 517 | 2016 |
| Validation of prediction models for critical care outcomes using natural language processing of electronic health record data BJ Marafino, M Park, JM Davies, R Thombley, HS Luft, DC Sing, DS Kazi, ... JAMA network open 1 (8), e185097-e185097, 2018 | 95 | 2018 |
| Variation in quality of urgent health care provided during commercial virtual visits AJ Schoenfeld, JM Davies, BJ Marafino, M Dean, C DeJong, NS Bardach, ... JAMA internal medicine 176 (5), 635-642, 2016 | 79 | 2016 |
| Assessment of national coverage and out-of-pocket costs for sacubitril/valsartan under Medicare Part D C DeJong, DS Kazi, RA Dudley, R Chen, CW Tseng JAMA cardiology 4 (8), 828-830, 2019 | 47 | 2019 |
| Incorporating a new technology while doing no harm, virtually C DeJong, CR Lucey, RA Dudley Jama 314 (22), 2351-2352, 2015 | 47 | 2015 |
| Deferral of care for serious non–COVID-19 conditions: a hidden harm of COVID-19 C DeJong, MH Katz, K Covinsky JAMA Internal Medicine 181 (2), 274-274, 2021 | 38 | 2021 |
| The risks of prescribing hydroxychloroquine for treatment of COVID-19—first, do no harm C DeJong, RM Wachter JAMA internal medicine 180 (8), 1118-1119, 2020 | 35 | 2020 |
| An ethical framework for allocating scarce inpatient medications for COVID-19 in the US C DeJong, AH Chen, B Lo JAMA 323 (23), 2367-2368, 2020 | 33 | 2020 |
| Out-of-pocket costs for novel guideline-directed diabetes therapies under Medicare Part D C DeJong, C Masuda, R Chen, DS Kazi, RA Dudley, CW Tseng JAMA internal medicine 180 (12), 1696-1699, 2020 | 27 | 2020 |
| Websites that offer care over the Internet: is there an access quality tradeoff? C DeJong, J Santa, RA Dudley Jama 311 (13), 1287-1288, 2014 | 26 | 2014 |
| Medicare Part D plans’ coverage and cost-sharing for acute rescue and preventive inhalers for chronic obstructive pulmonary disease CW Tseng, J Yazdany, RA Dudley, C DeJong, DS Kazi, R Chen, GA Lin JAMA internal medicine 177 (4), 585-588, 2017 | 25 | 2017 |
| Reconsidering physician–pharmaceutical industry relationships C DeJong, RA Dudley Jama 317 (17), 1772-1773, 2017 | 22 | 2017 |
| Nationwide coverage and cost-sharing for PCSK9 inhibitors among Medicare Part D plans DS Kazi, CY Lu, GA Lin, C DeJong, RA Dudley, R Chen, CW Tseng JAMA cardiology 2 (10), 1164-1166, 2017 | 21 | 2017 |
| Association between industry marketing payments and prescriptions for PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors in the United States K Inoue, JF Figueroa, C DeJong, Y Tsugawa, EJ Orav, C Shen, DS Kazi Circulation: Cardiovascular Quality and Outcomes 14 (5), e007521, 2021 | 17 | 2021 |
| Tenofovir-based PrEP for COVID-19: an untapped opportunity? C DeJong, MA Spinelli, H Okochi, M Gandhi Aids 35 (9), 1509-1511, 2021 | 12 | 2021 |
| Patients’ compliance with quarantine requirements for exposure or potential symptoms of COVID-19 CW Tseng, Y Roh, C DeJong, LN Kanagusuku, KS Soin Hawai'i journal of health & social welfare 80 (11), 276, 2021 | 10 | 2021 |
| Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries JAMA Intern Med, 176 (2016) C DeJong, T Aguilar, CW Tseng, GA Lin, WJ Boscardin, RA Dudley CrossRef View in Scopus, 1114, 0 | 10 | |
| Continuing problems with financial conflicts of interest and clinical practice guidelines C DeJong, R Steinbrook JAMA Internal Medicine 178 (12), 1715-1715, 2018 | 9 | 2018 |
| The inflation reduction act and out-of-pocket drug costs for medicare beneficiaries with cardiovascular disease DS Kazi, C DeJong, R Chen, RK Wadhera, CW Tseng Journal of the American College of Cardiology 81 (21), 2103-2111, 2023 | 6 | 2023 |
| Inclusion across the lifespan in cardiovascular trials—A long road ahead C DeJong, K Covinsky JAMA Internal Medicine 180 (11), 1533-1534, 2020 | 5 | 2020 |
